newsfilter
← Latest News
Business Wire·

Forma Therapeutics Announces Presentations at Upcoming Hematology Conferences

Updated results from the completed Phase 1 study of etavopivat in patients with sickle cell disease (SCD) Study design for the Phase 2 Gladiolus Study of etavopivat in patients with transfusion-dependent (TD) SCD or non-TD/TD thalassemia Forma T